Advanced search
Publication Cover
Molecular & Cellular Oncology Volume 9, 2022 - Issue 1
Submit an article Journal homepage
1,472
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Immunogenic cell stress and injury versus immunogenic cell death: implications for improving cancer treatment with immune checkpoint blockade

Ganapathy Srirama David. H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USAView further author information
,
Tiffany R. Emmonsa David. H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA;b Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA;c Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA;d Center for Precision Cancer Medicine, Massachusetts Institute of Technology, Cambridge, MA, USAView further author information
,
Lauren E. Millinga David. H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA;b Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USAView further author information
,
Darrell J. Irvinea David. H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA;b Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA;e Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA;f The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA;g Howard Hughes Medical Institute, Chevy Chase, MD, USAView further author information
&
Michael B. Yaffea David. H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA;b Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA;c Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA;d Center for Precision Cancer Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA;h Divisions of Acute Care Surgery, Trauma, and Surgical Critical Care and Surgical Oncology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9547-3251View further author information
ORCID Icon
Article: 2039038 | Received 11 Dec 2021, Accepted 02 Feb 2022, Published online: 03 Apr 2022

Figures & data

Figure 1. Immunogenic cell stress/injury stimulates an anti-tumor immune response.

Following stress and injury, including chemotherapy-induced DNA damage, antigens from the tumor cells are either released from the cells or displayed on the surface at higher levels, together with stress-activated ligands. In the conventional model (a), DCs cross-present these antigens on MHC-I to prime and activate CD8+ T-cells. A minor but substantial fraction of CD8+ T-cell priming, however, occurs through direct tumor cell:T-cell contact following stress and damage (b). Finally, our observation that only live stressed/injured cells were capable of driving DC-mediated T-cell priming indicates that antigen delivery to, and/or stimulation of DCs involves direct tumor cell:DC contact (c), and even allows the possibility of a 3-way interaction between the tumor cells, DCs, and T-cells (d). Figure created with BioRender.com.
Figure 1. Immunogenic cell stress/injury stimulates an anti-tumor immune response.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.